Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cholesterol, HDL

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    670 result(s) found for: Cholesterol, HDL. Displaying page 6 of 34.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2005-005981-35 Sponsor Protocol Number: NK-104-309 Start Date*: 2006-06-22
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: DOUBLE-BLIND FOLLOW-ON STUDY OF PITAVASTATIN (4 MG) VERSUS SIMVASTATIN (40 MG AND 80 MG), WITH A SINGLE-BLIND EXTENSION OF TREATMENT, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLI...
    Medical condition: Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-005756-10 Sponsor Protocol Number: GEM-301 Start Date*: 2016-05-06
    Sponsor Name:Gemphire Therapeutics Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients with Hypercholesterolemia on a High-Intensity Stable Statin Therap...
    Medical condition: Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001033-15 Sponsor Protocol Number: NK-104-302 Start Date*: 2005-08-01
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: STUDY OF PITAVASTATIN 2 MG vs. SIMVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA
    Medical condition: PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA
    Disease: Version SOC Term Classification Code Term Level
    7.1 10020604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001715-30 Sponsor Protocol Number: RIMON_R_00962 Start Date*: 2006-10-23
    Sponsor Name:sanofi aventis Groupe
    Full Title: A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with...
    Medical condition: abdominally obese patients with dyslipidemia with or without other comorbidities
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) CZ (Completed) SI (Completed) NL (Completed) SE (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) SK (Completed) HU (Completed) GR (Completed) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004556-30 Sponsor Protocol Number: LPS15021 Start Date*: 2018-08-24
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: A Multicenter, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Formulation of Zenon (Ezetimibe/Rosuvastatin Fixed Dose Combination) in Patien...
    Medical condition: Patients with Primary Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004682-14 Sponsor Protocol Number: OM-EPA-011 Start Date*: 2014-04-15
    Sponsor Name:Omthera Pharmaceuticals, Inc.
    Full Title: A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
    Medical condition: Severe hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-002263-15 Sponsor Protocol Number: LIXISL07016 Start Date*: 2014-10-10
    Sponsor Name:sanofi aventis S.p.A
    Full Title: Effects of GLP-1 Receptor Agonist Lixisenatide on Post-prandial Lipid Profile in Obese Type 2 Diabetic Patients
    Medical condition: Effect of GLP-1 receptor agonist lixisenatide on post-prandial lipid profile in obese patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001289-14 Sponsor Protocol Number: MIT-Do001-C301 Start Date*: 2020-02-05
    Sponsor Name:Estetra SRL
    Full Title: A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comf...
    Medical condition: Moderate to Severe Vasomotor Symptoms (VMS) in Postmenopausal Women
    Disease: Version SOC Term Classification Code Term Level
    21.0 10047065 - Vascular disorders 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) LT (Completed) CZ (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2005-005980-27 Sponsor Protocol Number: NK-104-308 Start Date*: 2006-05-04
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: OPEN-LABEL, LONG-TERM ( ≥ 1 YEAR) EXTENSION STUDY OF PITAVASTATIN 2 MG AND 4 MG QD IN ELDERLY PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA
    Medical condition: Patients with Primary Hypercholesterolemia or Combined Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020604 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003766-85 Sponsor Protocol Number: DFI14223 Start Date*: 2017-08-03
    Sponsor Name:sanofi-aventis recherche&developpement
    Full Title: An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Heterozygous Familial Hypercholesterolemia Followed ...
    Medical condition: Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) CZ (Completed) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004711-21 Sponsor Protocol Number: 20130287 Start Date*: 2016-06-06
    Sponsor Name:Amgen Inc.
    Full Title: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hyperch...
    Medical condition: Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    19.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    19.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001917-20 Sponsor Protocol Number: R727-CL-1216.03 Start Date*: 2015-02-27
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia Undergoing Lipid A...
    Medical condition: Heterozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002757-18 Sponsor Protocol Number: CKJX839C12301 Start Date*: 2020-12-21
    Sponsor Name:Novartis Pharma AG
    Full Title: Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability, and efficacy of inclisiran in ad...
    Medical condition: Heterozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) NO (Completed) DE (Completed) SI (Completed) NL (Completed) GR (Completed) FR (Completed) IT (Completed) PL (Completed) HR (Completed) SK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001446-25 Sponsor Protocol Number: FHGT002 Start Date*: 2017-09-20
    Sponsor Name:University of Pennsylvania
    Full Title: AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH)
    Medical condition: Adults with homozygous familial hypercholesterolemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002007-13 Sponsor Protocol Number: CXUO320BDE35 Start Date*: 2006-06-29
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, active-controlled, open-label, multicenter cross-over study with two 6-week treatment periods to investigate the effect of the combination of Lescol XL (fluvastatin) 80 mg and fenofib...
    Medical condition: Dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    5.1 10058108 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001899-32 Sponsor Protocol Number: RESINFENOL Start Date*: 2017-08-17
    Sponsor Name:Dr. Abelardo Aguilera Peralta
    Full Title: Crossover and randomized clinical trial on the effect of Resincolestiramine in the intestinal absorption of new uremic toxins in patients in hemodialysis with chronic renal insufficiency
    Medical condition: Chronic renal insufficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003450-10 Sponsor Protocol Number: ISIS 301012-CS6 Start Date*: 2008-10-02
    Sponsor Name:Genzyme Europe B.V.
    Full Title: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 in Patients with Familial Hypercholesterolemia or Severe Hypercholesterolemia
    Medical condition: Patients with homozygous and heterozygous familial hypercholesterolemia or severe hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005469-20 Sponsor Protocol Number: DRI6589 Start Date*: 2007-02-15
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A randomized, double-blind, parallel-group, placebo-controlled, ezetimibe-calibrated, multicenter study evaluating the safety and efficacy of four doses and two dose-regimens of AVE5530 over 4 week...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-006557-28 Sponsor Protocol Number: FENOPRA-III-06-1 Start Date*: 2007-05-07
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A phase III, four-armed, randomised, double blind, parallel study to compare the efficacy and safety in type 2 diabetic patients with combined hyperlipidemia of a 12-week administration of Fenofibr...
    Medical condition: Type 2 diabetic patients, as defined by the WHO without CVD and with CVD (Cardiovascular disease), with combined hyperlipidemia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002364-29 Sponsor Protocol Number: 015 Start Date*: 2005-09-02
    Sponsor Name:
    Full Title: A Two Year Study to Assess the Efficacy, Safety, and Tolerability of MK-0364 in Obese Patients
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    7.1 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NO (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 07:23:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA